Report prepared for the health technology assessment panel of the NHS executive on the diagnosis, management, treatment and costs of prostate cancer in England and Wales

British Journal of Urology

Volumn 79, Issue SUPPL. 3, 1997, Pages 1-32

  Chamberlain, J ^a   Melia, J ^a   Moss, S ^a   Brown, J ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; ANALGESIC AGENT; ANTIANDROGEN; BICALUTAMIDE; CLODRONIC ACID; CORTICOSTEROID; CYPROTERONE ACETATE; DIETHYLSTILBESTROL; ESTRAMUSTINE PHOSPHATE; FLUTAMIDE; FOSFESTROL; GONADORELIN DERIVATIVE; GOSERELIN; KETOCONAZOLE; LAXATIVE; LEUPRORELIN; LOCAL ANESTHETIC AGENT; MEGESTROL ACETATE; NILUTAMIDE; PROSTATE SPECIFIC ANTIGEN; STEROID; STRONTIUM 89; SURAMIN; TRIMETHOPRIM; TUMOR MARKER; UNCLASSIFIED DRUG;

ADRENAL INSUFFICIENCY; ADULT; AGED; ANEMIA; BONE METASTASIS; BONE PAIN; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; COST EFFECTIVENESS ANALYSIS; DIGESTIVE SYSTEM FUNCTION DISORDER; GENETIC PREDISPOSITION; GRANULOCYTOPENIA; GYNECOMASTIA; HEALTH CARE COST; HUMAN; IMPOTENCE; INTRAVENOUS DRUG ADMINISTRATION; LENGTH OF STAY; LIVER DYSFUNCTION; MALE; NEUROTOXICITY; ORCHIECTOMY; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; REVIEW; RISK FACTOR; SUBCUTANEOUS DRUG ADMINISTRATION; URETER CATHETERIZATION;

ADULT; AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; GENETIC PREDISPOSITION TO DISEASE; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; INCIDENCE; MALE; MASS SCREENING; MIDDLE AGED; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REFERRAL AND CONSULTATION; RISK FACTORS; WORKLOAD;

EID: 0031397611     PISSN: 00071331     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (146)

1. Duncan BM, Garraway WM. Prostatic surgery for benign hyperplasia: meeting the expanding demand. Br J Urol 1993; 72: 761-5
2. Office of Population Censuses & Surveys. National Population Projections 1992-based. Report and Microfiche Giving Population Projections by Sex and Age for the United Kingdom, Great Britain and Constituent Countries. Prepared by the Government Actuary in consultation with the Registrars General. Series PP2 no. 19. London: HMSO, 1994
3. Swerdlow A, dos Santos Silva I. Atlas of Cancer Incidence in England and Wales 1968-1985. Oxford: Oxford University Press, 1995
4. General Register Office. Code of Surgical Operations with Classifications of Radiotherapy and Anaesthetic Procedures. London: HMSO, 1956
5. Scottish Cancer Intelligence Unit. Cancer Registration Statistics Scotland 1981-1990. Edinburgh: ISO Publications, 1993
6. Coleman M, Esteve J, Damiecke P, Arsland A, Renard H. Trends in Cancer Incidence and Mortality. Lyon: IARC, 1993
7. Potosky AR, Kessler L, Gridley G, Brown CC, Horm JW. Rise in prostatic cancer incidence associated with increased use of transurethral resection. J Natl Cancer Inst 1990; 82: 1624-7
8. Stephenson RA, Smart CR, Mineau GP, James BC, Janerich DT, Dibble RL. The fall in incidence of prostate cancer. On the down side of a prostate specific antigen induced peak in incidence-data from the Utah Cancer Registry. Cancer 1995; 77: 1342-8
9. Office for National Statistics. Mortality Statistics: Cause. England & Wales. 1993 (revised) and 1994. Series DH2 no. 21. London: HMSO, 1996
10. Office of Population Censuses & Surveys. Mortality Statistics: cause 1984. London: HMSO, 1985
11. Office of Population Censuses & Surveys. Occupational Mortality Decennial. Suppl. Series DS no. 6. Part II. Microfiche tables. London: HMSO, 1986
12. Mebane C, Gibbs T, Horm J. Current status of prostate cancer in North American black males. J Natl Med Assoc 1990; 82: 782-8
13. Office of Population Censuses & Surveys. Cancer Statistics. Incidence, Survival and Mortality in England and Wales. no. 43. London: HMSO, 1981
14. Cancer Research Campaign. Survival-England & Wales. Factsheet 2, 1988
15. Wilson JM, Kemp IW, Stein GJ. Cancer of the prostate. Do younger men have a poorer survival rate? Br J Urol 1984; 56: 391-6
16. Office of Population Censuses & Surveys. Morbidity Statistics from General Practice. Fourth National Study 1991-1992. Series MBS no. 3. London: HMSO, 1995
17. Emberton M, Neal DE, Black N et al. The National Prostatectomy Audit: the clinical management of patients during hospital admission. Br J Urol 1995; 75: 301-16
18. Office of Health Economics. Compendium of Health Statistics, 9th edn. London: 1995
19. Department of Health. Hospital Episode Statistics. Vol. 1. Finished Consultant Episodes by Diagnosis, Operation and Speciality. England: Financial Year 1993-94. London: HMSO, 1995
20. CIPFA Health Database. 1990 Health Service Trends. Detailed Tables. Chameleon Press, 1990
21. Department of Health & Social Security. 1985 Hospital in-patient Enquiry. Summary Tables. England. Series MB4 no. 26. London: HMSO, 1987
22. Department of Health. Hospital Episode Statistics. Vol. 1. Finished Consultant Episodes by Diagnosis, Operation and Speciality. England: Financial Year 1989-90. London: HMSO, 1993
23. Garraway WM, Collins GN, Lee RJ. High prevalence of benign prostatic hypertrophy in the community. Lancet 1991; 338: 469-371
24. Franks LM. Latent carcinoma of the prostate. J Pathol Bacterial 1954; 68: 603-16
25. Whittemore AS, Keller JB, Betensky R. Low-grade, latent prostate cancer volume: predictor of clinical cancer incidence? J Natl Cancer Inst 1991; 83: 1231-5
26. Yatani R, Chigusa I, Akazaki K, Stemmermann GN, Welsh RA, Correa P. Geographic pathology of latent prostatic carcinoma. Int J Cancer 1982; 29: 611-61
27. Resnick MI. Staging. J Urol 1992; 147: 881-2
28. McNeal JE, Villers AA, Redwine EA, Freiha FS, Stamey TA. Histologie differentiation, cancer volume, and pelvic lymph node metastasis in adenocarcinoma of the prostate. Cancer 1990; 66: 1225-33
29. Chodak GW. The role of conservative management in localized prostate cancer. Cancer 1994; 74: 2178-81
30. Caine M. Reflections on alpha blockade therapy for benign prostatic hyperplasia. Br J Urol 1995; 75: 265-9
31. MRC, Working Party on Prostate Cancer. Total Prostatectomy, Radiotherapy or No Immediate Treatment for Early Prostate Cancer. A Randomised Trial. (PRO6). Cambridge: MRC Cancer Trials Office, 1994
32. Ward AM, Green K. FreeJtotal PSA in the diagnosis of prostate carcinoma [AbstractJ. Proc ACB National Meeting 1995; 170
33. Oesterling JE, Jacobsen SJ, Chute CG et al. Serum prostatespecific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA 1993; 270: 860-4
34. Hudson MA, Bahnson RR, Catalona WJ. Clinical use of prostate specific antigen in patients with prostate cancer. JUrol 1989; 142: 1011-17
35. Brawer MK, Chetner MP, Beatie J, Buchner DM, Vessella RL. Lange PH. Screening for prostatic carcinoma with prostate specific antigen. J Urol 1992; 147: 841-5
36. Catalona WJ. Patient selection for, results, and impact on tumor resection of potency-sparing radical prostatectomy. Urol Clin North Am 1990; 17: 819-26
37. Parkes CA. An epidemiologist's viewpoint on screening. Cancer Surv 1995; 23: 127-40
38. Thompson IM, Ernst JJ, Gangai MP, Spence CR. Adenocarcinoma of the prostate: results of routine urological screening. J Urol 1984; 132: 690-2
39. Lee F, McHugh TA, Soloman MH et al. Transrectal ultrasound, digital rectal examination, and prostatespecific antigen: preliminary results of an early detection program for prostate cancer. Scand J Urol Nephrol 1991; vol?; 101-5
40. Mettlin C, Lee F, Drago J, Murphy G, the Investigators of the American Cancer Society National Prostate Cancer Detection Project. The American Cancer Society National Prostate Cancer Detection Project. Findings on the Detection of Early Prostate Cancer in 2425 men. Cancer 1991; 67: 2949-58
41. Palken M. Cobb OE, Simons CE, Warren BH, Aldape HC. Prostate cancer: comparison of digital rectal examination and transrectal ultrasound for screening. J Urol 1991; 145: 86-90
42. Richie JP, Kavoussi LR, Ho GT et al. Prostate cancer screening: role of the digital rectal examination and prostate-specific antigen. Ann Surg Oncol 1994; 1: 117-20
43. Perrin P, Maquet JH, Bringeon G, Devonec M. Screening for prostate cancer. Comparison of transrectal ultrasound, prostate specific antigen and rectal examination. Br J Urol 1991: 68: 263-5
44. Chodak GW, Keller P, Schoenberg HW. Assessment of screening for prostate cancer using the digital rectal examination. J Urol 1989; 141: 1136-8
45. Hammerer P, Loy V, Dieringer J, Huland H. Prostate cancer in nonurological patients with normal prostates on digital rectal examination. J Urol 1992; 147: 833-6
46. Catalona WJ, Smith DS, Ratliffe T. et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991; 324: 1156-61
47. Labrie F. Dupont A, Suburu R et al. Serum prostate specific antigen as pre-screening test for prostate cancer. J Urol 1992; 147: 846-52
48. Gann PH. Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA 1995; 273: 289-94
49. Parkes C, Wald NJ, Murphy P et al. Prospective observational study to assess value of prostate specific antigen as screening test for prostate cancer. BMJ 1995; 311: 1340-3
50. Lankford SP, Peters KL, Eiser RC. Potential effects of age-specific reference ranges for serum prostate-specific antigen. Ear Urol 1995; 27: 182-6
51. Mettlin C, Littrup PJ, Kane RA et al. Relative sensitivity and specificity of serum prostate specific antigen (PSA) level compared with age-referenced PSA, PSA density, and PSA change. Data from the American Cancer Society National Prostate Cancer Detection Project. Cancer 1994; 74: 1615-20
52. Petteway J, Brawer MK. Age specific vs. 4.0 ngJmL as a PSA cutoff in the screening population: impact on cancer detection [AbstractJ. Proc Am Urol Assoc 1995; 153: 945
53. Smith DS, Catalona WJ. Rate of change in serum prostate specific antigen levels as a method for prostate cancer detection. J Urol 1994; 152: 1163-7
54. Pearson JD, Carter HB, Metter EJ et al. Sensitivity and specificity of age-specific reference ranges for PSA velocity [AbstractJ. Proc Am Urol Assoc 1995; 153: 947
55. Imai K, Suzuki T, Yamanaka H et al. Mass screening for prostate cancer and the bias relating to survival rate. Urology International 1993; 51: 133-41
56. Friedman GD, Hiatt RA, Quesenberry CP, Selby JV. Casecontrol study of screening for prostatic cancer by digital rectal examinations. Lancet 1991; 337: 1526-9
57. Kirby RS, Kirby MG, Feneley MR, McNicholas T, McLean A, Webb JA. Screening for carcinoma of the prostate: a GP based study. Br J Urol 1994; 74: 64-71
58. Chadwick DJ, Kemple T, Astley JP et al. Pilot study of screening for prostate cancer in general practice. Lancet 1991; 338: 613-16
59. Adami H-0, Baron JA, Rothman KJ. Ethics of a prostate cancer screening trial. Lancet 1994; 343: 958-60
60. Gohagan JK, Prorok PC, Kramer BS, Hayes RB, Cornett JE. The Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial of the National Cancer Institute. Cancer 1995: 75: 1869-73
61. Schröder FH, Denis LJ, Kirkels W, de Koning HJ, Standaert B. European randomized study of screening for prostate cancer. Progress report of Antwerp and Rotterdam Pilot Studies. Lancet 1996 (accepted for publication)
62. Auvinen A, Rietbergen JBW, Denis LJ, Schroder FH, Prorok PC, for the International Prostate Cancer Screening Trial Evaluation Group. Prospective evaluation plan for
63. randomised trials of prostate cancer screening. J Med Screening 1996; 3: 97-104
64. Hardcastle p, Chamberlain J, Sheffield J et al Randomised controlled trial of faecal occult blood screening for colorectal cancer. Results of the first, 107,349 subjects. Lancet 1989; i: 1160-4
65. Chodak GW, Schoenberg HW. Progress and problems in screening for carcinoma of the prostate. World J Surg 1989; 13: 60-4
66. Pedersen KV, Carlsson P, Varenhorst E, Lofman 0, Berglund K. Screening for carcinoma of the prostate by digital rectal examination in a randomly selected population. BMJ 1990; 300: 1041-4
67. Benoît RM, Naslund MJ. An economic rationale for prostate cancer screening. Urology 1994; 44: 795-803
68. Love RR, Fryback DG, Kimbrough SR. A cost-effectiveness analysis of screening for carcinoma of the prostate by digital examination. Med Decis Making 1985; 5: 263-78
69. Krahn MD, Mahoney JE, Eckman MH, Trachtenberg J, Pauker SG, Detsky AS. Screening for prostate cancer. A decision analytic view. JAMA 1994; 272: 773-80
70. Department of Health. A Policy Framework for Commissioning Cancer Services. A report by the Expert Advisory Group on Cancer to the Chief Medical Officers of England and Wales. London: Department of Health, 1995
71. de las Morenas A, Siroky MB, Merriam J, Stilmant MM. Prostatic adenocarcinoma: Reproducibility and correlation with clinical stages of four grading systems. Hum Pathol 1988; 19: 595-7
72. Humphrey PA, Walthier PJ. Adenocarcinoma of the prostate. II. Tissue prognosticators. Am J Clin Pathol 1993; 100: 256-69
73. Rohr LR. Incidental adenocarcinoma in transurethral resections of the prostate. Partial vs. complete microscopic examination. Am J Surg Pathol 1987; 11: 53-8
74. Murphy WM, Dean PJ, Brasfleld JA, Tatum L. Incidental carcinoma of the prostate. How much sampling is adequate? Am J Surg Pathol 1986; 10: 170-5
75. Vollmer RT. Prostate cancer and chip specimens: complete vs. partial sampling. Hum Pathol 1986; 17: 285-90
76. Newman AJ, Graham MA, Carlton CE, Lieman S. Incidental carcinoma of the prostate at the time of transurethral resection; importance of evaluating every chip. J Urol 1982; 128: 948-52
77. Levy IG, Gibbons L, Collins JP, Perkins DG, Mao Y. Prostate cancer trends in Canada: rising incidence or increased detection? Can Med Assoc J 1993; 149: 617-23
78. Harnden P, Parkinson MC. Macroscopic examination of prostatic specimens. J Clin Pathol 1995; 48: 693-700
79. Kirby RS, Christmas TJ, Brawer M. Prostate Cancer. London, Baltimore: Mosby-Wolfe, Times Mirror International Publishers Limited, 1995
80. George NJR. Natural history of localised prostatic cancer managed by conservative therapy alone. Lancet 1988; i: 494-7
81. Chodak GW, Thisted RA, Gerber GS et al. Results of conservative management of clinically localised prostate cancer. N Engl J Med 1994; 330: 242-8
82. Litwin MS. Health-related quality of life after treatment for localized prostate cancer. Cancer 1995; 75: 2000-3
83. Kornblith AB, Herr HW, Ofman US, Scher HI, Holland JC. Quality of life of patients with prostate cancer and their spouses. The value of a data base in clinical care. Cancer 1994; 73: 2791-802
84. Dearnaley DP. Radiotherapy for Prostate Cancer. The Changing Scene. Clin Oncol 1995; 7: 147-50
85. Adolfsson J. Radical prostatectomy, radiotherapy or deferred treatment for localized prostate cancer? Cancer Surv 1995; 23: 141-8
86. Hanks GE. Radiotherapy or surgery for prostate cancer? Ten and fifteen-year results of external beam therapy. Acta.Oncol 1991; 30:231-7
87. el Galley RE, Howard GC, Hawkyard S et al. Radical radiotherapy for localized adenocarcinoma of the prostate. A report of 191 cases. Br J Urol 1995; 75: 38-43 8 7 Hanks GE. Radical prostatectomy or radiation therapy for
88. early prostate cancer: Two roads to the same end. Cancer 1988:61:2153-60
89. Schellhammer PF, El-Mahdi AM. Pelvic complications after definitive treatment of prostate cancer by intestitial or external beam radiation. Urology 1983; 21: 451-7
90. Catalona WJ. Management of cancer of the prostate. N EnglJMed 1994; 331: 996-1004
91. Murphy GP, Mettlin C, Menck H, Winchester DP, Davidson AM. National patterns of prostate cancer treatment by radical prostatectomy: results of a survey by the American College of Surgeons Commission on Cancer. J Urol 1994; 152: 1817-19
92. Walsh PC, Partin AW, Epstein II. Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years. J Urol 1994; 152: 1831-6
93. Gibbons RP. Total prostatectomy for clinically localised prostate cancer: long term surgical results and current morbidity. In Wittes RD, ed., Consensus Development Conference on the Management of Clinically Localised Prostate Cancer. Washington, DC: NCI, 1988: 123-6
94. Lepor H, Walsh PC. Long-term results of radical prostatectomy in clinically localised prostate cancer: experience at the John Hopkins Hospital. In Wittes RD, ed., Consensus Development Conference on the Management of Clinically Localised Prostate Cancer. Washington, DC: NCI, 1988: 117-22
95. Gerber GS, Thisted RA, Chodak GW et al. Results of radical prostatectomy in men with clinically localized prostate cancer: multi-institutional analysis. Proc Am Urol Ass 1995; 153: 252A
96. Wasson JH, Cushman CC, Bruskewitz RC et al. A structured literature review of treatment for localized prostate cancer. Arch Pam Med 1993; 2: 487-93
97. Fowler JEJr, Braswell NT, Pandey P, Seaver L. Experience with radical prostatectomy and radiation therapy for localized prostate cancer at a Veterans Affairs Medical Center. J Urol 1995; 153: 1026-31
98. Jonler M, Messing EM, Rhodes PR, Bruskewitz RC. Sequelae of radical prostatectomy. Br }Urol 1994; 74: 352-8
99. Braslis KG, Santa-Cruz C, Brickman AL, Soloway MS. Quality of life 12 months after radical prostatectomy. Br J Urol 1995; 75: 48-53
100. Litwin MS, Hays RD, Fink A et al Quality of life outcomes in men treated for localized prostate cancer. JAMA 1995; 273: 129-35
101. Fleming C, Wasson JH, Albertsen PC. Barry MJ, Wennberg JE, the Prostate Disease Patient Outcome Research Team. A decision analysis of alternative treatment strategies for clinically localized prostate cancer. JAMA 1993; 269: 2650-8
102. Norlen BJ. Swedish randomized trial of radical prostatectomy vs. watchful waiting. Can J Oncol 1994; 4: 38-40
103. Wilt TJ, Brawer MK. The Prostate Cancer Intervention Versus Observation Trial: a randomised trial comparing radical prostatectomy vs. expectant management for the treatment of clinically localized prostate cancer. J Urol 1994; 152: 1910-14
104. Andriole GL. Finateride induced PSA reduction in patients with early stage prostate cancer. J Urol 1994; 151: 450A
105. Labrie F, Dupont A, Cusan L et al. Downstaging of localized prostate cancer by neoadjuvant therapy with Flutamide and Lupron: the first controlled and randomized trial. Clin Invest Med 1993; 16: 499-509
106. Partin AW, Piantadosi S, Sanda MG et al. Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy. Vrology 1995; 45: 831-8
107. Debruyne FM, Denis L, Lunglmayer G et al. Long-term therapy with a depot luteinizing hormone-releasing hormone analogue (Zoladex) in patients with advanced prostatic carcinoma. J Urol 1988; 140: 775-7
108. Parmar H, Phillips RH, Lightman SL, Edwards L. How would you like to have an orchidectomy for advanced prostatic cancer? Am J Clin Oncol 1988; 11: S160-8
109. Harper ME, Pike A, Peeling WB et al. Steroids of adrenal origin metabolized by human prostate tissue both in vivo and in vitro. J Endocrinol 1984; 60: 117
110. Crawford ED, Eisenberger MA. McLeod DG et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989; 321: 419-24
111. Den LJ, Carnelro de Moura JL, Bono A et al. Goserelin acetate and flutamide vs. bilateral orchidectomy: a phase III EORTC trial (30853). EORTC GU Group and EORTC Data Center. Urology 1993; 42: 119-29
112. Keuppens F, Denis L, Smith P et al. Zoladex and flutamide vs. bilateral orchidectomy. A randomized phase III EORTC 30853 study. The EORTC GU Group. Cancer 1990; 66: 1045-57
113. Canadian Anandron Study Group. Total androgen blockade in the treatment of metastatic prostate cancer. Sem in Urol 1990; 8: 159-65
114. Janknegt RA. International Anandron Study Group: Efficacy and tolerance of a total androgen blockade with Anandron and orchidectomy. A double-blind, placebo controlled multicentre study. J Urol 1991; 145: 425A
115. Lunglmayr A. A multicentre trial comparing the luteinizing hormone releasing hormone analog Zoladex, with Zoladex plus flutamide in the treatment of advanced prostate cancer. The International Prostate Cancer Study Group. Eur Urol 1990; 18: 28-9
116. Iversen P, Suciu S, Sylvester R, Christensen I, Denis L. Zoladex and flutamide vs. orchidectomy in the treatment of advanced prostate cancer. A combined analysis of two European studies. EORTC 30853 and DAPROCA 86. Cancer 1990; 66: 1067-73
117. Prostate Cancer Triallists Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomized trials with 3283 deaths in 5710 patients. Lancet 1995; 346: 265-9
118. Waymont B, Lynch TH. Dünn JA et al. Phase III Randomised study of Zoladex vs. Stilboestrol in the treatment of advanced prostate cancer. Br J Urol 1992; 69: 614-20
119. Peto R. Gray R, Collins R et al. Randomised trial of prophylactic daily aspirin in British male doctors. BMJ 1988; 296: 313-16
120. Dearnaley DP. Radiotherapy of prostate cancer: established results and new developments. Sem Surg Oncol 1995; 11: 50-9
121. Freiha FS, Bagshaw MA. Carcinoma of the prostate: results of post-irradiation biopsy. Prostate 1984; 5: 19-23
122. Lewington V. McEwan AJ, Ackery DM et al. A prospective randomized double-blind crossover study to examine the efficacy of Strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone. Eur J Cancer 1991; 27: 954-8
123. Quilty PM, Kirk D, Böiger JT et al. A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. Radiotherapy and Oncology 1994; 31: 33-40
124. Soloway MS, Beckley S, Brady MF et al. A comparison of estramustine phosphate vs. cis-platinum alone vs. estramustine phosphate plus cis-platinum in patients with advanced hormone refractory prostate cancer who had had extensive irradiation to the pelvis or lumbosacral area. J UroJ1983; 129: 56-61
125. Vorreuther R. Biphosphonates as an adjunct to palliative therapy of bone métastases from prostatic carcinoma. A pilot study on clodronate. Br J Urol 1993; 72: 792-5
126. MRC, Working Party on Prostate Cancer. Oral Sodium Clodronate for Locally Advanced Prostatic Adenocarcinoma. A Double-blind, Placebo Controlled Randomised Trial. (PRO4). Cambridge: MRC Cancer Trials Office. 1994
127. MRC. Working Party on Prostate Cancer. Oral Sodium Clodronate for Metastatic Prostate Adenocarcinoma. A Doubleblind, Placebo Controlled Randomised Trial. (PROS). Cambridge: MRC Cancer Trials Office, 1994
128. Carter BS, Carter FIB, Isaacs JT. Epidemiologie evidence regarding predisposing factors to prostate cancer. Prostate 1990; 16: 187-97
129. Rooney C, Beral V, Maconochie N, Fraser P, Davies G. Case-control study of prostate cancer in employees of United Kingdom Atomic Energy Authority. BMJ 1993; 307: 1391-7
130. Messina MJ, Persky V, Setchell KD et al. Soy intake and cancer risk: a review of the in vitro and in vivo data. Nutr Cancer 1994; 21: 113-31
131. Peterson G, Barnes S. Genistein and biochanin A inhibit the growth of human prostate cancer cells but not epidermal growth factor receptor tyrosine autophosphorylation. Prostate 1993;vol? 335-45
132. Mousavi Y, Adlercreutz H. Genistein is an effective stimulator of sex hormone-binding globulin production in hepatocarcinoma human liver cancer cells and suppresses proliferation of these cells in culture. Steroids 1993; 58: 301-4
133. Brawer MK, Ellis WJ. Chemoprevention for prostate cancer. Cancer 1995; 75: 1783-9
134. Ross RK, Henderson BE. Do diet and androgens alter prostate cancer risk via a common etiologic pathway? J Natl Cancer Inst 1994; 86: 252-4
135. Steinberg GD, Carter BS, Beaty TH, Childs B, Walsh PC. Family history and the risk of prostate cancer. Prostate 1990; 17: 337-47
136. Carter BS, Beaty TH, Steinberg GD, Childs B, Walsh PC. Mendelian inheritance of familial prostate cancer. Proc Nat Acad Sci USA 1992; 89: 3367-71
137. Office of Population Censuses & Surveys. 1971-1989 Cancer Statistics: registrations. England and Wales. Series MB 1 no. 1-22. London: HMSO, 1979
138. Knudson AGJ. Hereditary cancer, oncogenes, and antioncogenes. Cancer Res 1985; 45: 1437-43
139. Atkin NB, Baker MC. Chromosome 7q deletions; observations on 13 malignant tumours. Cancer Genet Cytogenet 1993; 67: 123-5
140. Brothman AR, Peehl DM, Patel AM, McNeal JE. Frequency and patterns of karyotypic abnormalities in human prostate cancer. Cancer Res 1990; 50: 3795-803
141. Carter BS, Ewing CM, Ward WS et al. Allelic loss of chromosomes 16q and lOq in human prostate cancer. Proc Nat Acad Sci USA 1990; 87: 8751-5
142. Collins VP, Kunimi K, Bergerheim U, Eckman P. Molecular genetics and human prostatic carcinoma. Acta Oncol 1991; 30: 181-5
143. Bova GS, Isaacs SD, Partin AW. Biological aggressiveness of hereditary prostate cancer (HPC): long term evaluation following radical prostatectomy. J Urol 1995; 154: 505A
144. Eeles RA, Dearnaley DP, Ardern-Jones A et al. The search for genes predisposing to familial prostate cancer: a cancer research campaign collaborative study. Surgery 1995; 13 (8): 180A-B
145. Office of Population Censuses & Surveys. 1989 Cancer Statistics: registrations England & Wales. Series MB1 no. 22. London: HMSO, 1994
146. Office of Population Censuses & Surveys. 1992 Mortality Statistics General. England and Wales. Series DH no. 27. London: HMSO, 1994